NCT06689111 Correlation of Typical LBBB Mechanical Activation Pattern by 2D Strain Echocardiography With Acute GWE Improvement in Patients Receiving LBBp or Conventional BiVp for Cardiac Resynchronization Therapy (Echo LBBp)
| NCT ID | NCT06689111 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital of Patras |
| Condition | Heart Failure With Reduced Ejection Fraction (HFrEF) |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-05-23 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2024-05-23 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The present study is a multicenter interventional non randomised study in patients requiring an implantable device for cardiac resynchronization therapy. Its primary objective is to investigate whether the presence of a specific echocardiographic contraction pattern before implantation is associated with increased rates of acute improvement in myocardial function (as measured by an ultrasound) and to compare the improvement in two groups of patients based on the type of pacing (biventricular or left-sided pacing)
Eligibility Criteria
Inclusion Criteria: * \>18 years \< 90 years * Patients with a documented indication for resynchronization therapy \[symptomatic patients despite optimal medication, HFrEF (EF\<35%), LBBB QRS morphology\] * COMPLETE LBBB (LBBB defined as QRS\>130msec, wide "notched or slurred" R wave in leads I, aVL, V5, V6 and occasional RS pattern in V5, V6, absence of Q waves in leads I, V5 and V6 but in lead aVL narrow Q wave may be present in the absence of myocardial pathology, R peak time \>60ms in leads V5 and V6 but normal in leads V1, V2, V3 when small R's are discernible in precardial leads, ST and T usually opposite to QRS direction) * Patients with ntraventricular septum diameter \>8 mm * Written informed consent Exclusion Criteria: * Patients with RBBB or atypical LBBB QRS morphology * Patients eligible for an upgrade procedure (already carring a PM or ICD) * Patients with hypertrophic cardiomyopathy
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06689111 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Heart Failure With Reduced Ejection Fraction (HFrEF). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06689111 currently recruiting?
Yes, NCT06689111 is actively recruiting participants. Contact the research team at levent2669@hotmail.com for enrollment information.
Where is the NCT06689111 trial being conducted?
This trial is being conducted at Pátrai, Greece.
Who is sponsoring the NCT06689111 clinical trial?
NCT06689111 is sponsored by University Hospital of Patras. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.